Speakers
Jonah Rainey, PhD
VP of Antibody Engineering and Protein Science
AlivaMab Discovery Services
Daniel Bedinger
Application Science Manager
Carterra
Track B Day 2 AM
11:00 am | High throughput SPR characterization of multi-specific antibodies. Capabilities and workflow approaches advancing discovery
Giorgio Salciarini
Marketing & Business Development Manager
BSP
Day One
Wednesday, September 21 | 2022
8:50 am | Looking to Satisfy the Growing Demand of Capacity and Capabilities for Biologics
Alexander Haas
Head Biologics Core Technologies
Roche
Track B Day 2 PM
1:00 pm | Graphical Design, Engineering & In Silico Cloning of Multispecific Antibodies
Aman Singh
Associate Director, Cell Therapy Clinical Pharmacology, Modeling & Bioinformatics
Takeda
Track A Day 2 AM
10:30 am | Translational PK/PD Investigations & Multiscale Mechanism-Based Modeling to Support Development of T Cell Redirecting Antibodies
Ankita Srivastava
Vice President - Protein Sciences & Rational Design
Ichnos Sciences
Track B Day 2 PM
1:30 pm | TREAT 2.0: A Versatile Platform Technology for Development of Multispecific Antibodies
Anthony Stein
Medical Doctor
City of Hope
Day Two
Thursday, September 22 | 2022
3:30 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting
3:00 pm | Improving Bispecific Antibody Outcome in Acute Myeloid Leukemia
Azra Mujic-Delic
Principal Scientist - Functional Characterization & Bioassays
Genmab
Track B Day 2 AM
11:00 am | Potency Assay Strategy from Early to Late Clinical Development: A Bispecifics Case Study
Brandon Leonard
Principal Scientific Researcher - Antibody Engineering
Genentech
Colette Johnston
Vice President Discovery
Crescendo Biologics
Day One
Wednesday, September 21 | 2022
4:15 pm | CB307: A Novel T Cell Costimulatory Humabody VH Therapeutic for PSMA-Positive Tumors
Chava Kimchi-Sarfaty
Deputy Associate Director - Research Office of Tissue & Advanced Therapies
CBER, FDA
Track B - Day 1 PM
2:15 pm | VIRTUAL: Exploring the Consequences of Codon Optimization on Therapeutic Sequences
Christopher Mehlin
Chief Scientific Officer & Co-founder
Link Immunotherapeutics
Day One
Wednesday, September 21 | 2022
9:00 am | Panel Discussion – Different Viewpoints of Bi & Multi Specifics in the Field
Focus Day Track A - PM
1:30 pm | Roundtable Discussion - Understanding Different Formats Behavior to Identify Which One Works Best
Pre-Conference Focus Day
10:20 am | Chair’s Opening Remarks
Daniel Pereira
Chief Scientific Officer
Invenra
Day Two
Thursday, September 22 | 2022
9:05 am | Uncovering the Therapeutic Potential of a Next Generation Tumor Treg Deplete
Diego Ellerman
Principal Scientific Researcher
Genentech
Track A - Day 1 PM
1:15 pm | CLEC5a-Directed Bispecific Antibody for Effective Cellular Phagocytosis
Erin Meermeier
Research Associate Scientist - Division of Hematology and Oncology
Mayo Clinic
Focus Day Track A - AM
11:00 am | Evaluating Novel formats & Testing Efficacy in Fully Immunosufficient in vivo Models
Eugene Zhukovsky
Chief Scientific Officer
Ichnos Sciences
Day One
Wednesday, September 21 | 2022
9:00 am | Panel Discussion – Different Viewpoints of Bi & Multi Specifics in the Field
Ezio Bonvini
Chief Scientific Officer
Macrogenics
Track A Day 2 PM
1:30 pm | Overcoming the Challenges of a First-Generation CD123-Directed Bispecific CD3-Engaging DART Molecule
Harald Kolmar
Department Head Applied Biochemistry
Technical University of Darmstadt
Focus Day Track A - AM
10:30 am | A Productive Relationship for NK Cell Engagement: Multispecific Two-In-One Antibodies
Jeffrey Way
Lecturer - Department of Systems Biology
Harvard Medical School
Track B - Day 1 PM
2:45 pm | Rational Engineering of an Erythropoietin Fusion Protein to Treat Hypoxia”
Jonathan Davis
Vice President - Innovation and Strategy
Invenra
Track B - Day 1 PM
1:45 pm | Correlating Multispecific Structures to their Functions for a Holistic Overview of Product Design
Julia Frei
Principal Scientist
Ichnos Sciences
Track B - Day 1 PM
1:15 pm | ISB 1442, a First-in-Class 2+1 Fc Engineered Biparatopic Bispecific BEAT® 2.0 antibody targeting CD38 and CD47
Kalyan Pande
Associate Principal Scientist – Protein Engineering & Modalities
Merck
Focus Day Track A - PM
1:00 pm | Multimerization of Single-Domain Antibodies Targeting Viral Glycoproteins for Enhanced Potency
Liqin Liu
Senior Director of T Cell Engagers
IGM Biosciences
Focus Day Track B - AM
11:30 am | IGM-2323 - High Avidity IgM-Based CD20xCD3 Bispecific Antibody for Enhanced T Cell Dependent Killing with Minimal Cytokine Release
Martin Siegemund
Senior Scientist
Pieris Pharmaceuticals
Focus Day Track A - AM
11:30 am | Anticalin Proteins as Key Components in Advanced Multispecific Formats
Nimish Gera
Vice President - Biologics Research
Mythic Therapeutics
Focus Day Track B - PM
1:30 pm | Roundtable Discussion - Evaluating Tumor Toxicity for Immune Cell Re-Targeting
Pranjali Dalvi
Senior Scientist
Amgen
Track A Day 2 PM
1:00 pm | Decoupling Cytotoxicity with Cytokine Release: Development of Safe CD3 T Cell Engagers for Solid Tumors
Prathap Shastri
Scientific Director, DMPK, Preclinical Sciences and Translational Safety
Johnson & Johnson
Track A - Day 1 PM
2:45 pm | Retrospective Look at Translational Considerations & FIH Dosing Approaches for T-cell Redirectors
Rakesh Dixit
President and Head of R&D, Co-Founder
Regio Biosciences
Track A - Day 1 AM
10:45 am | On and Off-Target Toxicities of Bispecific Targeted Biologics: Mitigation Strategies
Shailee Patel
Researcher
Beacon Targeted Therapeutics
Day One
Wednesday, September 21 | 2022
8:20 am | The Landscape of Bi/Multispecifics
Shaun Lippow
Vice President, Drug Discovery & Protein Engineering
Atreca
Track B - Day 1 AM
10:45 am | Engineering Safe & Effective Bispecific Immunotherapies for Solid Tumor Indications
Suzanne Schubbert
Associate Director - Discovery Biology & Pharmacology
Xencor
Focus Day Track B - PM
1:00 pm | LAG3-Targeted IL15/IL15Rα-Fc (LAG3 x IL15) Fusion Protein for Preferential TIL Expansion
Vera Sellers
Associate Director - Molecule Group, Protein & Cell Sciences Discovery & Development Technologies
EMD Serono
Track A - Day 1 AM
11:15 am | Early Developability of Multispecifics
Wadim Matochko
Scientist Antibody Discovery
Amgen
Wei Yan
President & Chief Executive Officer
Sound Biologics
Focus Day Track B - AM
11:00 am | Rationale Design of the Next Generation Bifunctional Checkpoint Inhibitors
Werner Meier
Chief Scientific Officer
Revitope Oncology
Day Two
Thursday, September 22 | 2022
9:45 am | Guided Antibody Tumor Engagers (TwoGATE™), a Sophisticated & Differentiated Approach for T Cell Redirection in Solid Tumors
Yanchen Zhou
Principle Scientist
Amgen
John Burke
Co-Founder, President & Chief Executive Officer
Applied BioMath
Musheng Bao
Senior Director, Discovery Oncology
Harbour Biomed
Track A Day 2 PM
2:00 pm | Generation of Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecifics for Solid Tumor Therapies
Christel Iffland, PhD.
VP, Antibody Technology
OmniAb, Inc.
Track B - Day 1 AM
11:45 am | High Specificity OmniAb Antibodies for Bispecific Applications
Alexander Schinagl
Chief Technology Officer
OncoOne
Track A Day 2 AM
11:00 am | PreTarg-it®: A modular platform utilizing bispecific antibodies for optimized biodelivery of payloads.
John Burke, PhD
Co-Founder, President, and CEO
Applied BioMath
Track B Day 2 AM
11:30 am | Model-Informed Drug Discovery & Development Aids in the Design & Dose Prediction for Multispecific Therapeutics
Ken Howard
Associate Professor and Group Leader
Aarhus University
Focus Day Track B - AM
10:30 am | Programmable Half-Life & Anti-Tumour Effects of Bi-Specific T-Cell Engager-Albumin Fusions with Tuned FcRn Affinity
Laura von Schantz
Vice President Discovery
Alligator Bioscience
Day One
Wednesday, September 21 | 2022
9:00 am | Panel Discussion – Different Viewpoints of Bi & Multi Specifics in the Field
Day Two
Thursday, September 22 | 2022
3:30 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting
Track A - Day 1 PM
1:45 pm | Kick-Starting Tumor Specific T Cell Cross-Priming Using Neo-X-Prime Bispecific Antibodies Targeting CD40
Anna Von Rossum
Scientist of Multispecific Antibody Therapeutics
Zymeworks
Track A - Day 1 PM
2:15 pm | Expanding the Therapeutic Window for Immune- Engaging Multi-Specifics Through Conditional Activation & Co-Stimulation
Daniel Bedinger
Application Science Manager
Carterra
Jan Schnitzer
Chief Executive Officer & President
Proteogenomics Research Institute for Systems Medicine (PRISM)
Day Two
Thursday, September 22 | 2022
3:30 pm | Panel Discussion - Unlocking the Potential of Combinatorial Strategies of Bispecifics in a Clinical Setting
Track B - Day 1 AM
11:15 am | Bispecific Antibodies Engineered to be Pumped into Disease Tissue for Ultra-Low Dose Therapeutic Efficacy
Giorgio Salciarini
Marketing & Business Development Manager
BSP Pharmaceuticals
Mark Moore
Chief Executive Officer
Gempharmatech
Day Two
Thursday, September 22 | 2022
9:35 am | Humanized Mouse Models for Development of Bispecific Antibody Therapeutics
Weisheng Chen
Founder & Chief Executive Officer
Leveragen
Day One
Wednesday, September 21 | 2022
9:35 am | Singularity Sapiens: A Novel Genetically Engineered Mouse for Developing Fully Human Nanobodies and Multi-specific Antibodies
Matthew Romei
Antibody Engineering Research Fellow
Genentech
Track B Day 2 PM
2:00 pm | Leveraging Homotypic Antibody Interfaces for Biotherapeutic Engineering
Your 2022 Expert Speakers
